Chronic Graft versus Host Disease (GvHD) is a serious complication that develops in the majority of patients that have received an allogeneic hematopoietic stem cell transplantation (HSCT). Chronic GvHD has many resemblances with autoimmune diseases. Currently, treatment with cyclosporine and corticosteroids is one of the standard therapies. Many patients, however, become refractory to these standard regimens over time. At present, though, there are no good alternatives and the prognosis of refractory patients is therefore poor.
Kiadis Pharma’s Rhitol™ has been developed to treat steroid refractory chronic GvHD. Rhitol™ eliminates the patients' auto reactive immune cells that cause chronic GvHD. Patients undergo a treatment with Rhitol™ with regular intervals aiming to result in an immune modulation effect within the patient and remission of the disease by restoring immuno-tolerance.